Oct 10, 2020
Curious about science's latest
effort to reverse aging? This podcast describes attainable
treatments and the science behind theses
gene therapy processes: Elizabeth Parrish discusses BioViva's
anti-aging gene therapy products and research. Even better, she
brings a different perspective—she has had viral vector gene
therapy herself.
Listen and learn
Elizabeth Parrish is a returning
guest and CEO of BioViva, a leader in health regenerative gene
therapy. She takes listeners on a tour of anti-aging science,
offering interesting and intelligent descriptions of available
therapies and exciting future treatments in the works.
She begins by describing four specific therapies BioViva offers
through Integrated Health Systems: telomerase gene-inducement,
myostatin inhibitors, mitochondrial improvement, and klotho gene
therapy. Respectively, these address anti-aging, muscle growth,
energy production, and organ systems and dementia
issues.
The process for how they
accomplish these therapies is better than science fiction.
Essentially, they use a viral vector that has had its pathogenesis
removed. They fill this vector with the gene therapy and a
promotor, which regulates the amount of gene delivered. These
therapies are introduced into the body through various ways, but
most frequently through an IV drip.
She adds that clients will need to take an immune suppressant
before and after this therapy, though usually it is on the milder
side and tends to be prednisone or something similar. What really
makes this interview interesting is Elizabeth's ability to explain
how the biology behind this therapy works, why telomere length
makes a difference, and how this turns on health-inducing genes
without actually changing a person's DNA.
In other words, it's not genetic engineering for extending life
spans, it's gene therapy for enhancing and strengthening what the
body already has.
For more about the company,
see bioviva-science.com.
Available on Apple Podcasts: apple.co/2Os0myK